Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
نویسندگان
چکیده
منابع مشابه
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
TLR agonists have demonstrated anti-tumor activity in both animals and humans. Clinically, successful antitumor activity with TLR agonists was most often observed when the molecules were applied locally to dermatological cancers. This mode of administration was also associated with fewer and less severe adverse events (AEs) when compared to systemic administration. The efficacy of TLR agonists ...
متن کاملIntratumoral TNFα improves immunotherapy
Solid tumors are frequently resistant to immunotherapy. We demonstrated that low-dose tumor necrosis factorα (TNFα), when directly targeted to the tumor environment, exerts dual effects by improving vessel functionality and activating immune cells. This vascular remodeling in an inflammatory context enhances active immunotherapy and promotes tumor regression.
متن کاملIntratumoral immunotherapy of established solid tumors with chitosan/IL-12.
IL-12 is a potent antitumor cytokine that exhibits significant clinical toxicities after systemic administration. We hypothesized that intratumoral (i.t.) administration of IL-12 coformulated with the biodegradable polysaccharide chitosan could enhance the antitumor activity of IL-12 while limiting its systemic toxicity. Noninvasive imaging studies monitored local retention of IL-12, with and w...
متن کاملInduction of systemic anti-melanoma immunity through intratumoral TLR-7/8 activation
Purpose Intratumoral immune activation can induce systemic immunity and anti-tumor activity. Imiquimod is a creamformulated, TLR-7 agonist that is FDA-approved for the treatment of non-melanoma skin cancers, but has limited activity against melanoma. In the current study, we studied the anti-tumor activity and mechanism of action of a novel injectable TLR 7/8 dual agonist, 3M-052, which remains...
متن کاملA "prime-pull" immunotherapy approach using a lentiviral vector and intratumoral TLR4 agonist redirects cytotoxic T cells
Methods B16F10-OVA melanoma bearing C57BL/6 mice were immunized with the lentiviral vector DCVex on 10 days after tumor challenge to induce OVA specific effector and memory CD8 T cells. Mice were then treated 12 days later intratumorally with the TLR4 agonist GLAAS (glucopyranosyl adjuvant system), which induces the T cell homing chemokines CXCL9 and CXCL10. Control mice received no treatment o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal for ImmunoTherapy of Cancer
سال: 2013
ISSN: 2051-1426
DOI: 10.1186/2051-1426-1-s1-p138